MarzanoAV, TrevisanV, LazzariR. Pyoderma gangrenosum: study of 21 patients and proposal of a 'clinicotherapeutic' classification. J Dermatolog Treat2011;22:254–60, doi:10.3109/09546631003686069.
Richter-HintzD, SchuppeHC, HomeyB. Topical tacrolimus (FK 506) is effective in the treatment of pyoderma gangrenosum. J Am Acad Dermatol2000;42:304–5, doi:10.1016/S0190-9622(00)90149-X.
8.
BelliniV, SimonettiS, LisiP.Successful treatment of severe pyoderma gangrenosum with pimecrolimus cream 1%. J Eur Acad Dermatol2008;22:113–5.
9.
AlricL, LarocheM, FaucheuxJM. Systemic manifestations of hemorrhagic rectocolitis: apropos of a case of hemorrhagic rectocolitis associated with multiple sclerosis. Rev Med Interne1997;18:132–7, doi:10.1016/S0248-8663(97)84679-6.
GhislainPD, De DeckerI, MarotL. Efficacy and systemic absorption of topical tacrolimus used in pyoderma gangrenosum. Br J Dermatol2004;150:1052–3, doi:10.1111/j.1365-2133.2004.05914.x.
13.
KontosAP, KerrHA, FivensonDP. An open-label study of topical tacrolimus ointment 0.1% under occlusion for the treatment of pyoderma gangrenosum. Int J Dermatol2006;45:1383–5, doi:10.1111/j.1365-4632.2006.03133.x.
14.
MarzanoAV, TrevisanV, LazzariR. Topical tacrolimus for the treatment of localized, idiopathic, newly diagnosed pyoderma gangrenosum. J Dermatolog Treat2010;21:140–3, doi:10.3109/09546630903268239.
15.
RegueiroM, ValentineJ, PlevyS. Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease. Am J Gastroenterol2003;98:1821–6, doi:10.1111/j.1572-0241.2003.07581.x.
16.
DiniV, RomanelliM, BertoneM. Improvement of idiopathic pyoderma gangrenosum during treatment with anti-tumor necrosis factor alfa monoclonal antibody. Int J Low Extrem Wounds2007;6:108–13, doi:10.1177/1534734607300912.
17.
CharlesCA, LeonA, BantaMR. Etanercept for the treatment of refractory pyoderma gangrenosum: a brief series. Int J Dermatol2007;46:1095–9, doi:10.1111/j.1365-4632.2007.03286.x.
18.
JacobSE, WeismanRS, KerdelFA. Pyoderma gangrenosum—rebel without a cure? Int J Dermatol2008;47:192–4, doi:10.1111/j.1365-4632.2008.03412.x.
